Related Experiment Video

Updated: Aug 3, 2025

In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis
09:43

In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis

Published on: August 4, 2011

18.1K

Inclisiran-A Revolutionary Addition to a Cholesterol-Lowering Therapy

Adrianna Dec1, Aleksandra Niemiec1, Eliza Wojciechowska1

  • 1Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia in Katowice, Medyków 18, 40-752 Katowice, Poland.

International Journal of Molecular Sciences
|April 13, 2023
PubMed

Insights

Inclisiran, a novel small interfering RNA (siRNA) therapy, effectively lowers LDL cholesterol by increasing LDL receptors. This drug shows promise for future lipid-lowering treatments due to its efficacy and favorable profile.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Molecular Biology

Background:

  • Hypercholesterolemia is a significant risk factor for atherosclerosis, often undertreated and underdiagnosed.
  • Lipid disorders have high prevalence, prolonged asymptomatic stages, and can lead to life-threatening complications.
  • Stringent LDL cholesterol targets are crucial for preventing cardiovascular events.

Purpose of the Study:

  • To describe inclisiran, a novel small interfering RNA (siRNA) therapeutic agent.
  • To elucidate the mechanism of action of inclisiran in lowering LDL cholesterol.
  • To evaluate the potential role of inclisiran in future hypolipemic therapies.

Main Methods:

  • Description of inclisiran as a small interfering RNA (siRNA) molecule.
  • Explanation of inclisiran's mechanism targeting PCSK9 to increase hepatic LDL receptors (LDLRs).

Main Results:

  • Inclisiran increases the number of LDL receptors (LDLRs) on hepatic cells.
  • Inclisiran prevents the synthesis of PCSK9, reducing LDLR degradation.
  • Potential for significant reduction in plasma LDL cholesterol levels.

Conclusions:

  • Inclisiran demonstrates high liver specificity and a convenient dosing regimen.
  • The drug exhibits good tolerance with no significant adverse effects.
  • Inclisiran holds significant potential for future hypolipemic therapies.

Keywords:
PCSK9 inhibitorshypercholesterolemiainclisiransiRNA

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
Cholesterol Efflux Assay07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

29.9K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
717
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
161
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
186
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
230
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
613
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16